bwin国际官方网站
FDA approves bwin中国制药 Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade
bwin中国制药 investigational atrasentan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
bwin中国制药 confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers
bwin中国制药 Financial Results – Q3 2023
bwin中国制药 announced the company’s financial results for the third quarter of 2023.
Treatments for blood cancers and serious blood disorders are advancing rapidly – bwin中国制药 is helping lead the way
bwin中国制药 has been at the forefront of advances in how blood cancers and serious blood disorders are treated, helping patients live their best lives.
bwin中国制药 in 社会 Integrated Report 2022
In 2022, we continued to reimagine medicine and deliver on our purpose to improve and extend people's lives.
Environmental, Social and Governance
We have a responsibility and opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.
The bwin中国制药 Commitment to 患者和护理人员
bwin中国制药 works with the patient community around the world to discover new ways to improve and extend people’s lives.